Wissenschaftliche Publikationen

Kreutz R, Deray G, Floege J, Gwechenberger M, Hahn K, Luft AR, Persson P, Axthelm C, Beer JH, Bergler-Klein J, Lellouche N, Taggeselle J, Coleman CI, Beyer-Westendorf J, XARENO registry.

Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.

Jacc: Advances. 2024 Feb; 3(2):100813. https://doi.org/10.1016/j.jacadv.2023.100813.

Zur digitalen Publikation

Pausch C, Pittrow D, Hoeper MM, Huscher D.

Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.

Eur Resp J. 2023 Nov 29;62(5):2301023. doi: 10.1183/13993003.01023-2023. Print 2023 Nov.

Zur digitalen Publikation

Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Noppeney T, Pittrow D, Klotsche J, Gerlach HE, Bauersachs R; INSIGHTS-SVT Study Collaborators.

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.

Eur J Vasc Endovasc Surg. 2023 Nov;66(5):697-704. doi: 10.1016/j.ejvs.2023.08.031. Epub 2023 Aug 12.

Zur digitalen Publikation

Tiede A, Hart C, Knöbl P, Greil R, Oldenburg J, Sachs UJ, Miesbach W, Pfrepper C, Trautmann-Grill K, Holstein K, Pilch J, Möhnle P, Schindler C, Weigt C, Schipp D, May M, Dobbelstein C, Pelzer FJ, Werwitzke S, Klamroth R.

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.

Lancet Haematol. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6. Epub 2023 Oct 16.

Zur digitalen Publikation

Fasshauer M, Borte M, Bitzenhofer M, Pausch C, Pittrow D, Park M, Gladiator A, Jandus P.

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.

Adv Ther. 2023 Sept 26. https://doi.org/10.1007/s12325-023-02649-0.

Zur digitalen Publikation

Kubasch AS, Peterlin P, Cluzeau T, Götze KS, Sockel K, Teipel R, Jentzsch M, Attalah H, Sebert M, Chermat F, Gloaguen S, Puttrich M, Cross M, Schneider M, Kayser S, Schipp D, Giagounidis A, Tirado-Gonzalez I, Descot A, Van de Loosdrecht AA, Weigert A, Metzeler KH, Fenaux P, Medyouf H, Platzbecker U, Ades L.

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.

Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029-1.

Zur digitalen Publikation

Dimou M, Speletas M, Milito C, Pyzik A, Huscher D, Kamieniak M, Pittrow D, Borte M.

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis.

Cancers 2023 Sept 12; 15(18), 4524. https://doi.org/10.3390/cancers15184524.

Zur digitalen Publikation

Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Noppeney T, Pittrow G, Klotsche J, Gerlach HE, Bauersachs R; INSIGHTS-SVT Study Collaborators.

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.

Eur J Vasc Endovasc Surg. 2023 Aug 11:S1078-5884(23)00654-8. doi: 10.1016/j.ejvs.2023.08.031. Online ahead of print.

Zur digitalen Publikation

Diehl-Wiesenecker E, Blaschke S, Wohmann N, Kubisch I, Stauch T, Mainert M, Helm F, von Wegerer S, Pittrow D, Frank J, Stölzel U, Somasundaram R.

Detect Acute Porphyrias in Emergency Departments (DePorED) - a pilot study.

Orphanet J Rare Dis. 2023 Jun 12;18(1):146. doi: 10.1186/s13023-023-02768-5.

Zur digitalen Publikation

Dong F, Kern I, Weidner J, Kügler K, Rothe U, Amin M, Laaß MW, Flemming G, Winkler U, Richter T, Kugler J, Manuwald U.

Clinical course of new-onset Crohn's disease in children and adolescents in dependency of age, initial location, initial severity level and therapy over the period 2000-2014 based on the Saxon Pediatric IBD-Registry in Germany.

PLoS One. 2023 Jun 29;18(6):e0287860. doi: 10.1371/journal.pone.0287860. eCollection 2023.

Zur digitalen Publikation

Schnabel D, Kreitschmann-Andermahr I, Strasburger C, Pittrow D, Pausch C, Woelfle J; INSIGHTS-GHT Study Group.

Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol).

Orphanet J Rare Dis. 2023 May 10;18(1):112. doi: 10.1186/s13023-023-02716-3.

Zur digitalen Publikation

Schmidt KH, Milger K, Pausch C, Huscher D, Pittrow D, Gruenig E, Staehler G, Gall H, Distler O, Skowasch D, Halank M, Wilkens H, Held M, Klose H, Hoeper M.

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis.

Eur Respir J. 2023 Apr 27;61(4):2202440. doi: 10.1183/13993003.02440-2022. Print 2023 Apr.

Zur digitalen Publikation

Borte M, Hanitsch LG, Mahlaoui N, Fasshauer M, Huscher D, Speletas M, Dimou M, Kamieniak M, Hermann C, Pittrow D, Milito C.

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.

J Clin Immunol. 2023 Apr 10;1-13. doi: 10.1007/s10875-023-01470-2. Online ahead of print.

Zur digitalen Publikation

Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, Nimubona S, Goasguen J, Wattel E, Zini G, Torregrosa Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Navarro R, Patriarca A, Stamatoullas A, Götze K, Puttrich M, Mossuto S, Solary E, Gloaguen S, Chevret S, Chermat F, Platzbecker U, Fenaux P.

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

J Clin Oncol. 2023 Apr 1;41(10):1888-1897. doi: 10.1200/JCO.22.00437. Epub 2022 Dec 1.

Zur digitalen Publikation

Behr J, Bonella F, Günther A, Koschel D, Prasse A, Pittrow D, Klotsche J, Kreuter M; INSIGHTS-ILD Study Group.

Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry.

BMC Pulm Med. 2023 Feb 11;23(1):64. doi: 10.1186/s12890-023-02333-7.

Zur digitalen Publikation

Rosenkranz S, Pausch C, Coghlan JG, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Delcroix M, Ghofrani HA, Ewert R, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Scelsi L, Neurohr C, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Remppis BA, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Lange TJ, Olsson KM, Hoeper MM, Opitz C

Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.

J Heart Lung Transplant. 2023 Jan;42(1):102-114. doi: 10.1016/j.healun.2022.10.003. Epub 2022 Oct 13.

Zur digitalen Publikation

Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L.

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7.

Zur digitalen Publikation

Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Park DH, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Lange TJ, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Swift AJ, Thompson AAR, Elliot CA, Rosenkranz S, Condliffe R, Kiely DG, Halank M.

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.

Lancet Respir Med. 2022 Oct;10(10):937-948. doi: 10.1016/S2213-2600(22)00097-2. Epub 2022 Jun 28.

Zur digitalen Publikation

Laufs U, Birkenfeld AL, Fraass U, Hohenstein B, Siegert C, Klotsche J, Steinhagen-Thiessen E, Pittrow D, Dexl S, Salmen S, Schettler VJJ, Parhofer KG; Collaborators in the PERI-DYS Study.

Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.

Cardiovasc Drugs Ther. 2022 Sep 30. doi: 10.1007/s10557-022-07386-0. Online ahead of print.

Zur digitalen Publikation

Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park DH, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Lange TJ, Rosenkranz S.

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.

Eur Respir J. 2022 Jul 7;60(1):2102311. doi: 10.1183/13993003.02311-2021. Print 2022 Jul.

Zur digitalen Publikation

Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Ewert R, Kaemmerer H, Kabitz HJ, Skowasch D, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H, Claussen M, Eisenmann S, Schmidt KH, Rosenkranz S, Lange TJ.

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.

J Heart Lung Transplant. 2022 Jul;41(7):971-981. doi: 10.1016/j.healun.2022.03.011. Epub 2022 Mar 22.

Zur digitalen Publikation

Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Park DH, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Seyfarth HJ, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S, Klose H.

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.

Eur Respir J. 2022 Jun 2;59(6):2102024. doi: 10.1183/13993003.02024-2021. Print 2022 Jun.

Zur digitalen Publikation

Baumann U, Fasshauer M, Pausch C, Wittkowski H, Hermann C, Pittrow D, Borte M.

Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.

Immunotherapy. 2022 Feb;14(2):135-143. doi: 10.2217/imt-2021-0167. Epub 2021 Nov 8.

Zur digitalen Publikation

Pistrosch F, Matschke JB, Schipp D, Schipp B, Henkel E, Weigmann I, Sradnick J, Bornstein SR, Birkenfeld AL, Hanefeld M.

Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.

Diabetologia. 2021 Dec;64(12):2701-2712. doi: 10.1007/s00125-021-05562-9. Epub 2021 Sep 8.

Zur digitalen Publikation

Kaemmerer AS, Gorenflo M, Huscher D, Pittrow D, Ewert P, Pausch C, Delcroix M, Ghofrani HA, Hoeper MM, Kozlik-Feldmann R, Skride A, Stähler G, Vizza CD, Jureviciene E, Jancauskaite D, Gumbiene L, Ewert R, Dähnert I, Held M, Halank M, Skowasch D, Klose H, Wilkens H, Milger K, Jux C, Koestenberger M, Scelsi L, Brunnemer E, Hofbeck M, Ulrich S, Vonk Noordegraaf A, Lange TJ, Bruch L, Konstantinides S, Claussen M, Löffler-Ragg J, Wirtz H, Apitz C, Neidenbach R, Freilinger S, Nemes A, Opitz C, Grünig E, Rosenkranz S.

Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.

Cardiovasc Diagn Ther. 2021 Dec;11(6):1255-1268. doi: 10.21037/cdt-21-351.

Zur digitalen Publikation

Olsson KM, Hoeper MM, Pausch C, Grünig E, Huscher D, Pittrow D, Rosenkranz S, Gall H.

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.

Eur Respir J. 2021 Aug 26;58(2):2101483. doi: 10.1183/13993003.01483-2021. Print 2021 Aug.

Zur digitalen Publikation

Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Benjamin N, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Jureviciene E, Paleviciute E, Miliauskas S, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Wirtz H, Pfeuffer-Jovic E, Harbaum L, Scholtz W, Dumitrescu D, Bruch L, Coghlan G, Neurohr C, Tsangaris I, Gorenflo M, Scelsi L, Vonk-Noordegraaf A, Ulrich S, Held M.

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.

J Heart Lung Transplant. 2020 Dec;39(12):1435-1444. doi: 10.1016/j.healun.2020.09.011. Epub 2020 Sep 30.

Zur digitalen Publikation

Haider KS, Haider A, Saad F, Doros G, Hanefeld M, Dhindsa S, Dandona P, Traish A.

Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.

Diabetes Obes Metab. 2020 Nov;22(11):2055-2068. doi: 10.1111/dom.14122. Epub 2020 Jul 15.

Zur digitalen Publikation

Kanwar MK, Gomberg-Maitland M, Hoeper M, Pausch C, Pittrow D, Strange G, Anderson JJ, Zhao C, Scott JV, Druzdzel MJ, Kraisangka J, Lohmueller L, Antaki J, Benza RL.

Risk stratification in pulmonary arterial hypertension using Bayesian analysis.

Eur Respir J. 2020 Aug 27;56(2):2000008. doi: 10.1183/13993003.00008-2020. Print 2020 Aug.

Zur digitalen Publikation

Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, Klotsche J, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Bahmer T, Oqueka T, Frankenberger M, Kreuter M.

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.

Eur Respir J. 2020 Aug 13;56(2):1902279. doi: 10.1183/13993003.02279-2019. Print 2020 Aug.

Zur digitalen Publikation

Kaemmerer H, Gorenflo M, Huscher D, Pittrow D, Apitz C, Baumgartner H, Berger F, Bruch L, Brunnemer E, Budts W, Claussen M, Coghlan G, Dähnert I, D'Alto M, Delcroix M, Distler O, Dittrich S, Dumitrescu D, Ewert R, Faehling M, Germund I, Ghofrani HA, Grohé C, Grossekreymborg K, Halank M, Hansmann G, Harzheim D, Nemes A, Havasi K, Held M, Hoeper MM, Hofbeck M, Hohenfrost-Schmidt W, Jurevičienė E, Gumbienè L, Kabitz HJ, Klose H, Köhler T, Konstantinides S, Köestenberger M, Kozlik-Feldmann R, Kramer HH, Kropf-Sanchen C, Lammers A, Lange T, Meyn P, Miera O, Milger-Kneidinger K, Neidenbach R, Neurohr C, Opitz C, Perings C, Remppis BA, Riemekasten G, Scelsi L, Scholtz W, Simkova I, Skowasch D, Skride A, Stähler G, Stiller B, Tsangaris I, Vizza CD, Vonk Noordegraaf A, Wilkens H, Wirtz H, Diller GP, Grünig E, Rosenkranz S.

Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.

J Clin Med. 2020 May 13;9(5):1456. doi: 10.3390/jcm9051456.

Zur digitalen Publikation

Kubasch AS, Schulze F, Giagounidis A, Götze KS, Krönke J, Sockel K, Middeke JM, Chermat F, Gloaguen S, Puttrich M, Weigt C, William D, Fenaux P, Schlenk RF, Thiede C, Stasik S, Mies A, Adès L, Oelschlägel U, Platzbecker U.

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Leukemia. 2020 Apr;34(4):1182-1186. doi: 10.1038/s41375-019-0645-z. Epub 2019 Dec 3.

Zur digitalen Publikation

Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, van Gemert T, Knebel B, Wolkersdorfer MF, Kuss O, Hwang JH, Bornstein SR, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld AL, Roden M.

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.

Diabetes Care. 2020 Feb;43(2):298-305. doi: 10.2337/dc19-0641. Epub 2019 Sep 20.

Zur digitalen Publikation

Harenberg J, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C; Working Group Members.

Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.

Thromb Haemost. 2020 Jan;120(1):132-140. doi: 10.1055/s-0039-1700545. Epub 2019 Nov 8.

Zur digitalen Publikation

Schindler C, Birkenfeld AL, Hanefeld M, Schatz U, Köhler C, Grüneberg M, Tschöpe D, Blüher M, Hasslacher C, Bornstein SR.

Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

Diabetes Ther. 2019 Feb;10(1):329-331. doi: 10.1007/s13300-018-0546-6.

Zur digitalen Publikation

Haider A, Haider K, Saad F, Hanefeld M.

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report.

SAGE Open Med Case Rep. 2019 Jan 16;7:2050313X18823454. doi: 10.1177/2050313X18823454. eCollection 2019.

Zur digitalen Publikation

von Loeffelholz C, Gissey LC, Schumann T, Henke C, Kurzbach A, Struck J, Bergmann A, Hanefeld M, Schatz U, Bornstein SR, Casella G, Mingrone G, Birkenfeld AL.

The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery.

Int J Obes (Lond). 2018 Dec;42(12):2057-2061. doi: 10.1038/s41366-018-0084-3. Epub 2018 May 24.

Zur digitalen Publikation

Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.

Diabet Med. 2018 Oct;35(10):1375-1382. doi: 10.1111/dme.13669. Epub 2018 Jun 6.

Zur digitalen Publikation

Krieger SM, Reimann M, Haase R, Henkel E, Hanefeld M, Ziemssen T.

Sudomotor Testing of Diabetes Polyneuropathy.

Front Neurol. 2018 Sep 26;9:803. doi: 10.3389/fneur.2018.00803. eCollection 2018.

Zur digitalen Publikation

Buchberger AK, Brettschneider D, Berg K, Jungmann D, Oehlmann J, Scheurer M, Oetken M.

Effects of metoprolol on aquatic invertebrates in artificial indoor streams.

J Environ Sci Health A Tox Hazard Subst Environ Eng. 2018 Jul 3;53(8):728-739. doi: 10.1080/10934529.2018.1444964. Epub 2018 Mar 14.

Zur digitalen Publikation

Honsek C, Kabisch S, Kemper M, Gerbracht C, Arafat AM, Birkenfeld AL, Dambeck U, Osterhoff MA, Weickert MO, Pfeiffer AFH.

Fibre supplementation for the prevention of type 2 diabetes and improvement of glucose metabolism: the randomised controlled Optimal Fibre Trial (OptiFiT).

Diabetologia. 2018 Jun;61(6):1295-1305. doi: 10.1007/s00125-018-4582-6. Epub 2018 Feb 28.

Zur digitalen Publikation

Graessler J, Mehnert CS, Schulte KM, Bergmann S, Strauss S, Bornstein TD, Licinio J, Wong ML, Birkenfeld AL, Bornstein SR.

Urinary Lipidomics: evidence for multiple sources and sexual dimorphism in healthy individuals.

Pharmacogenomics J. 2018 Apr;18(2):331-339. doi: 10.1038/tpj.2017.24. Epub 2017 Jun 13.

Zur digitalen Publikation

Schindler C, Birkenfeld AL, Hanefeld M, Schatz U, Köhler C, Grüneberg M, Tschöpe D, Blüher M, Hasslacher C, Bornstein SR.

Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

Diabetes Ther. 2018 Feb;9(1):37-47. doi: 10.1007/s13300-017-0330-z. Epub 2017 Nov 13.

Zur digitalen Publikation

Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR.

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Diabetes Care. 2018 Feb;41(2):258-266. doi: 10.2337/dc17-0417. Epub 2017 Dec 15.

Zur digitalen Publikation

Owens DR, Monnier L, Hanefeld M.

A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.

Diabetes Obes Metab. 2017 Dec;19(12):1645-1654. doi: 10.1111/dom.12998. Epub 2017 Jul 11.

Zur digitalen Publikation

Hanefeld M, Arteaga JM, Leiter LA, Marchesini G, Nikonova E, Shestakova M, Stager W, Gómez-Huelgas R.

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

Diabetes Obes Metab. 2017 Nov;19(11):1594-1601. doi: 10.1111/dom.12986. Epub 2017 Jun 7.

Zur digitalen Publikation

Stengel S, Stallmach A, Richter K, Landrock A, Hampe J, Bruns T.

Serum metabolic signatures in patients with overt hepatic encephalopathy.

J Hepatol. 2017 Nov;67(5):1114-1115. doi: 10.1016/j.jhep.2017.06.030. Epub 2017 Jul 6.

Zur digitalen Publikation

Hanefeld M, Engelmann K, Appelt D, Sandner D, Weigmann I, Ganz X, Pistrosch F, Köhler C, Gasparic A, Birkenfeld AL.

Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes.

PLoS One. 2017 Oct 9;12(10):e0184234. doi: 10.1371/journal.pone.0184234. eCollection 2017.

Zur digitalen Publikation

von Loeffelholz C, Lieske S, Neuschäfer-Rube F, Willmes DM, Raschzok N, Sauer IM, König J, Fromm MF, Horn P, Chatzigeorgiou A, Pathe-Neuschäfer-Rube A, Jordan J, Pfeiffer AFH, Mingrone G, Bornstein SR, Stroehle P, Harms C, Wunderlich FT, Helfand SL, Bernier M, de Cabo R, Shulman GI, Chavakis T, Püschel GP, Birkenfeld AL.

The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism.

Hepatology. 2017 Aug;66(2):616-630. doi: 10.1002/hep.29089. Epub 2017 Jun 26.

Zur digitalen Publikation

Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, Sahin K, Bauersachs R; SURPRISE investigators.

Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply.

Lancet Haematol. 2017 Jun;4(6):e254-e255. doi: 10.1016/S2352-3026(17)30086-8.

Zur digitalen Publikation

Hanefeld M, Traylor L, Gao L, Landgraf W.

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.

Cardiovasc Diabetol. 2017 May 19;16(1):66. doi: 10.1186/s12933-017-0548-0.

Zur digitalen Publikation

Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, Sahin K, Bauersachs R; SURPRISE investigators.

Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.

Lancet Haematol. 2017 Mar;4(3):e105-e113. doi: 10.1016/S2352-3026(17)30014-5. Epub 2017 Feb 16.

Zur digitalen Publikation

Hanefeld M, Raccah D, Monnier L.

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):311-321. doi: 10.1080/17425255.2017.1251579. Epub 2016 Nov 3.

Zur digitalen Publikation

Jungmann D, Berg K, Dieterich A, Frank M, Gräf T, Scheurer M, Schwarz S, Siewert C, Oetken M.

Health effects of metoprolol in epibenthic and endobenthic invertebrates-A basis to validate future in vitro biotests for effect-based biomonitoring.

J Environ Sci Health A Tox Hazard Subst Environ Eng. 2017 Feb 23;52(3):189-200. doi: 10.1080/10934529.2016.1246930. Epub 2016 Nov 11.

Zur digitalen Publikation

Jordan J, El-Armouche A, Hanefeld M, Bornstein SR, Birkenfeld AL.

Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.

Diabetes Care. 2016 Dec;39(12):e224-e225. doi: 10.2337/dc16-1588.

Zur digitalen Publikation

Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators.

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15.

Zur digitalen Publikation

Scholz GH, Hanefeld M.

Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases.

Visc Med. 2016 Oct;32(5):319-326. doi: 10.1159/000450866. Epub 2016 Oct 7.

Zur digitalen Publikation

Daniels MA, Kan C, Willmes DM, Ismail K, Pistrosch F, Hopkins D, Mingrone G, Bornstein SR, Birkenfeld AL.

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Pharmacogenomics J. 2016 Oct;16(5):399-410. doi: 10.1038/tpj.2016.54. Epub 2016 Jul 19.

Zur digitalen Publikation

Hanefeld M, Appelt D, Engelmann K, Sandner D, Bornstein SR, Ganz X, Henkel E, Haase R, Birkenfeld AL.

Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy.

Horm Metab Res. 2016 Sep;48(9):620. doi: 10.1055/s-0036-1585504. Epub 2016 Oct 18.

Zur digitalen Publikation

Hanefeld M, Frier BM, Pistrosch F.

Hypoglycemia and Cardiovascular Risk: Is There a Major Link?

Diabetes Care. 2016 Aug;39 Suppl 2:S205-9. doi: 10.2337/dcS15-3014.

Zur digitalen Publikation

Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy-Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators.

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.

Diabetes Care. 2016 Aug;39(8):1318-28. doi: 10.2337/dc16-0014. Epub 2016 May 23.

Zur digitalen Publikation

Hanefeld M, Monnier L, Schnell O, Owens D.

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials.

Diabetes Ther. 2016 Jun;7(2):187-201. doi: 10.1007/s13300-016-0153-3. Epub 2016 Feb 10.

Zur digitalen Publikation

Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL.

The metabolic vascular syndrome - guide to an individualized treatment.

Rev Endocr Metab Disord. 2016 Mar;17(1):5-17. doi: 10.1007/s11154-016-9345-4.

Zur digitalen Publikation

Koch CA, Bornstein SR, Birkenfeld AL.

Introduction to Hanefeld Symposium: 40+ years of metabolic syndrome.

Rev Endocr Metab Disord. 2016 Mar;17(1):1-4. doi: 10.1007/s11154-016-9356-1.

Zur digitalen Publikation

Engelmann J, Manuwald U, Rubach C, Kugler J, Birkenfeld AL, Hanefeld M, Rothe U.

Determinants of mortality in patients with type 2 diabetes: a review.

Rev Endocr Metab Disord. 2016 Mar;17(1):129-37. doi: 10.1007/s11154-016-9349-0.

Zur digitalen Publikation

Jordan J, Birkenfeld AL.

Cardiometabolic crosstalk in obesity-associated arterial hypertension.

Rev Endocr Metab Disord. 2016 Mar;17(1):19-28. doi: 10.1007/s11154-016-9348-1.

Zur digitalen Publikation

Pistrosch F, Hanefeld M.

Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies.

Curr Diab Rep. 2015 Dec;15(12):117. doi: 10.1007/s11892-015-0678-2.

Zur digitalen Publikation

Pistrosch F, Ganz X, Bornstein SR, Birkenfeld AL, Henkel E, Hanefeld M.

Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions.

Acta Diabetol. 2015 Oct;52(5):889-95. doi: 10.1007/s00592-015-0727-y. Epub 2015 Mar 10.

Zur digitalen Publikation

Schernthaner G, Durán-Garcia S, Hanefeld M, Langslet G, Niskanen L, Östgren CJ, Malvolti E, Hardy E.

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).

Diabetes Obes Metab. 2015 Jul;17(7):630-8. doi: 10.1111/dom.12461. Epub 2015 Apr 7.

Zur digitalen Publikation

Seibt R, Steputat A, Spitzer S, Druschke D, Scheuch K.

[Age-related effects on mental ability and their associations with personal characteristics among female teachers].

Gesundheitswesen. 2015 Jan;77(1):39-45. doi: 10.1055/s-0034-1367029. Epub 2014 Apr 3.

Zur digitalen Publikation

Hanefeld M, Bornstein SR, Barthel A.

[Modern medical treatment of type 2 diabetes].

Dtsch Med Wochenschr. 2014 Dec;139(49):2494-7. doi: 10.1055/s-0034-1387406. Epub 2014 Nov 25.

Zur digitalen Publikation

Hanefeld M, Berria R, Lin J, Aronson R, Darmon P, Evans M, Van Gaal L.

Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.

Adv Ther. 2014 Aug;31(8):861-72. doi: 10.1007/s12325-014-0146-4. Epub 2014 Aug 21.

Zur digitalen Publikation

Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, Zhou T, Muehlen-Bartmer I, Ratner RE.

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).

J Diabetes Complications. 2014 May-Jun;28(3):386-92. doi: 10.1016/j.jdiacomp.2014.01.012. Epub 2014 Jan 28.

Zur digitalen Publikation

Schnell O, Hanefeld M, Monnier L.

Self-monitoring of blood glucose: a prerequisite for diabetes management in outcome trials.

J Diabetes Sci Technol. 2014 May;8(3):609-14. doi: 10.1177/1932296814528134. Epub 2014 Apr 2.

Zur digitalen Publikation

Hanefeld M, Ganz X, Nolte C.

[Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2].

Herz. 2014 May;39(3):312-9. doi: 10.1007/s00059-014-4086-1.

Zur digitalen Publikation

Hanefeld M, Fleischmann H, Schiffhorst G, Bramlage P.

Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.

Diabetes Technol Ther. 2014 Apr;16(4):241-6. doi: 10.1089/dia.2013.0246. Epub 2013 Nov 14.

Zur digitalen Publikation

Hanefeld M, Sulk S, Helbig M, Thomas A, Köhler C.

Differences in Glycemic Variability Between Normoglycemic and Prediabetic Subjects.

J Diabetes Sci Technol. 2014 Mar;8(2):286-290. doi: 10.1177/1932296814522739. Epub 2014 Mar 2.

Zur digitalen Publikation

Wozel G, Blasum C.

Dapsone in dermatology and beyond.

Arch Dermatol Res. 2014 Mar;306(2):103-24. doi: 10.1007/s00403-013-1409-7. Epub 2013 Dec 6.

Zur digitalen Publikation

Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S, Hanefeld M.

Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias.

Diabetes Care. 2014 Feb;37(2):516-20. doi: 10.2337/dc13-0600. Epub 2013 Sep 16.

Zur digitalen Publikation

Hanefeld M, Duetting E, Bramlage P.

Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review.

Cardiovasc Diabetol. 2013 Sep 21;12:135. doi: 10.1186/1475-2840-12-135.

Zur digitalen Publikation

Haas BJ, Papanicolaou A, Yassour M, Grabherr M, Blood PD, Bowden J, Couger MB, Eccles D, Li B, Lieber M, MacManes MD, Ott M, Orvis J, Pochet N, Strozzi F, Weeks N, Westerman R, William T, Dewey CN, Henschel R, LeDuc RD, Friedman N, Regev A.

De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis.

Nat Protoc. 2013 Aug;8(8):1494-512. doi: 10.1038/nprot.2013.084. Epub 2013 Jul 11.

Zur digitalen Publikation

Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T, Hanefeld M.

Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.

Acta Diabetol. 2013 Aug;50(4):587-95. doi: 10.1007/s00592-012-0451-9. Epub 2013 Feb 21.

Zur digitalen Publikation

Hanefeld M, Bramlage P.

Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial.

Curr Diab Rep. 2013 Jun;13(3):342-9. doi: 10.1007/s11892-013-0366-z.

Zur digitalen Publikation

Hanefeld M.

Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability.

Expert Rev Endocrinol Metab. 2012 Jul;7(4):395-405. doi: 10.1586/eem.12.35.

Zur digitalen Publikation

Hanefeld M, Schaper F, Appelt D, Fuchs W.

Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.

Horm Metab Res. 2011 Dec;43(13):980-3. doi: 10.1055/s-0031-1291233. Epub 2011 Nov 8.

Zur digitalen Publikation

Böhm O, Leitsmann R, Plänitz P, Radehaus C, Schreiber M, Schaller M.

k-Restoring processes at carbon depleted ultralow-k surfaces.

J Phys Chem A. 2011 Jul 28;115(29):8282-7. doi: 10.1021/jp202851p. Epub 2011 Jul 1.

Zur digitalen Publikation

Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W.

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.

Cardiovasc Diabetol. 2011 Jul 14;10:65. doi: 10.1186/1475-2840-10-65.

Zur digitalen Publikation

Pistrosch F, Natali A, Hanefeld M.

Is hyperglycemia a cardiovascular risk factor?

Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S128-31. doi: 10.2337/dc11-s207.

Zur digitalen Publikation

Stahn A, Hanefeld M.

[Multimodal therapy of dyslipidemia].

Clin Res Cardiol Suppl. 2011 May;6:10-6. doi: 10.1007/s11789-011-0031-5.

Zur digitalen Publikation

Engler B, Koehler C, Hoffmann C, Landgraf W, Bilz S, Schoner C, Bornstein SR, Hanefeld M.

Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus.

Exp Clin Endocrinol Diabetes. 2011 Jan;119(1):59-61. doi: 10.1055/s-0030-1262874. Epub 2011 Jan 18.

Zur digitalen Publikation

Hanefeld M, Forst T.

Dapagliflozin, an SGLT2 inhibitor, for diabetes.

Lancet. 2010 Jun 26;375(9733):2196-8. doi: 10.1016/S0140-6736(10)60749-0.

Zur digitalen Publikation

Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H.

Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.

Diabet Med. 2010 Feb;27(2):175-80. doi: 10.1111/j.1464-5491.2009.02915.x.

Zur digitalen Publikation

Hanefeld M, Schönauer M, Forst T.

[Glycemic control and cardiovascular benefit: What do we know today?].

Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. doi: 10.1055/s-0029-1244853. Epub 2010 Feb 9.

Zur digitalen Publikation

Hanefeld M, Bornstein SR, Pistrosch F.

Shifting the disease management paradigm from glucose: what are the cons?

Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S353-6. doi: 10.2337/dc09-S338.

Zur digitalen Publikation

Hanefeld M.

The role of pioglitazone in modifying the atherogenic lipoprotein profile.

Diabetes Obes Metab. 2009 Aug;11(8):742-56. doi: 10.1111/j.1463-1326.2009.01048.x. Epub 2009 Jun 10.

Zur digitalen Publikation

Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, Stelzer J, Schmitz G.

Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.

Horm Metab Res. 2009 Feb;41(2):132-6. doi: 10.1055/s-0028-1119407. Epub 2009 Feb 12.

Zur digitalen Publikation

Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL.

Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.

Diab Vasc Dis Res. 2009 Jan;6(1):32-7. doi: 10.3132/dvdr.2009.006.

Zur digitalen Publikation

Leonhardt W, Pfützner A, Müller J, Pietzsch J, Forst T, Karagiannis E, Lübben G, Hanefeld M.

Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.

Atherosclerosis. 2008 Nov;201(1):155-62. doi: 10.1016/j.atherosclerosis.2008.01.007. Epub 2008 Apr 18.

Zur digitalen Publikation

Hanefeld M, Schaper F, Koehler C.

Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.

Cardiovasc Drugs Ther. 2008 Jun;22(3):225-31. doi: 10.1007/s10557-008-6091-1. Epub 2008 Feb 29.

Zur digitalen Publikation

Hanefeld M, Schaper F.

Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.

Expert Rev Cardiovasc Ther. 2008 Feb;6(2):153-63. doi: 10.1586/14779072.6.2.153.

Zur digitalen Publikation

Hanefeld M.

Is rosiglitazone associated with increased risk for cardiovascular events?

Nat Clin Pract Cardiovasc Med. 2007 Dec;4(12):648-9. doi: 10.1038/ncpcardio1030. Epub 2007 Oct 9.

Zur digitalen Publikation

Koehler C, Ott P, Benke I, Hanefeld M; DIG Study Group.

Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study.

Horm Metab Res. 2007 Sep;39(9):632-5. doi: 10.1055/s-2007-985816.

Zur digitalen Publikation

Hanefeld M.

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

Cardiovasc Diabetol. 2007 Aug 15;6:20. doi: 10.1186/1475-2840-6-20.

Zur digitalen Publikation

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Curr Med Res Opin. 2007 Jun;23(6):1329-39. doi: 10.1185/030079907X188152. Epub 2007 Apr 30.

Zur digitalen Publikation

Henkel E, Gallo S, Siegert G, Koehler C, Hanefeld M.

Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.

Blood Coagul Fibrinolysis. 2007 Jun;18(4):327-34. doi: 10.1097/MBC.0b013e32809cc90b.

Zur digitalen Publikation

Hanefeld M.

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.

Int J Clin Pract Suppl. 2007 Jun;61(153):20-7. doi: 10.1111/j.1742-1241.2007.01361.x.

Zur digitalen Publikation

Hanefeld M, Koehler C, Gallo S, Benke I, Ott P.

Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study.

Cardiovasc Diabetol. 2007 Apr 26;6:13. doi: 10.1186/1475-2840-6-13.

Zur digitalen Publikation

Hanefeld M, Schaper F, Ceriello A.

[History and definition(s) of metabolic syndrome].

Internist (Berl). 2007 Feb;48(2):117-25. doi: 10.1007/s00108-006-1786-5.

Zur digitalen Publikation

Hanefeld M, Patwardhan R, Jones NP; Rosiglitazone Clinical Trials Study Group.

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

Nutr Metab Cardiovasc Dis. 2007 Jan;17(1):13-23. doi: 10.1016/j.numecd.2005.12.003. Epub 2006 Mar 20.

Zur digitalen Publikation

Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T.

Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.

J Am Coll Cardiol. 2007 Jan 23;49(3):290-7. doi: 10.1016/j.jacc.2006.08.054. Epub 2007 Jan 8.

Zur digitalen Publikation

Hanefeld M.

[The metabolic syndrome: where are we going and for what benefits?].

Dtsch Med Wochenschr. 2006 Dec;131 Suppl 8:S236-9. doi: 10.1055/s-2006-956280.

Zur digitalen Publikation

Hanefeld M, Pfützner A, Forst T, Lübben G.

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.

Curr Med Res Opin. 2006 Jun;22(6):1211-5. doi: 10.1185/030079906X112598.

Zur digitalen Publikation

Hanefeld M, Metzler W, Köhler C, Schaper F.

[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy].

Herz. 2006 May;31(3):246-54; quiz 255. doi: 10.1007/s00059-006-2798-6.

Zur digitalen Publikation

Hanefeld M.

Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).

Endocr Pract. 2006 Jan-Feb;12 Suppl 1:56-9. doi: 10.4158/EP.12.S1.56.

Zur digitalen Publikation

Hanefeld M, Schaper F.

Prandial hyperglycemia: is it important to track and treat?

Curr Diab Rep. 2005 Oct;5(5):333-9. doi: 10.1007/s11892-005-0090-4.

Zur digitalen Publikation

Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M.

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.

Metabolism. 2005 Sep;54(9):1168-73. doi: 10.1016/j.metabol.2005.03.024.

Zur digitalen Publikation

Metzler W, Wronski R, Bewig B.

[The lethal ingestion of cigarettes in adults: does it really exist?].

Dtsch Med Wochenschr. 2005 Jun 17;130(24):1491-3. doi: 10.1055/s-2005-870844.

Zur digitalen Publikation

Hanefeld M.

Outcome studies in type 2 diabetes.

Curr Med Res Opin. 2005;21 Suppl 1:S41-8. doi: 10.1185/030079905X36477.

Zur digitalen Publikation

Hanefeld M, Köhler C.

[Screening, prevention and early therapy of type 2 diabetics].

MMW Fortschr Med. 2004 Sep 2;146(35-36):28-9, 31.

Zur digitalen Publikation

Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M.

Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.

J Clin Endocrinol Metab. 2004 Sep;89(9):4238-42. doi: 10.1210/jc.2003-032120.

Zur digitalen Publikation

Hanefeld M, Schaper F.

[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis].

Herz. 2004 Aug;29(5):480-7. doi: 10.1007/s00059-004-2608-y.

Zur digitalen Publikation

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T.

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.

Stroke. 2004 May;35(5):1073-8. doi: 10.1161/01.STR.0000125864.01546.f2. Epub 2004 Apr 8.

Zur digitalen Publikation

Temelkova-Kurktschiev T, Hanefeld M.

The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.

Exp Clin Endocrinol Diabetes. 2004 Feb;112(2):75-9. doi: 10.1055/s-2004-815753.

Zur digitalen Publikation

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Diabetes Care. 2004 Jan;27(1):141-7. doi: 10.2337/diacare.27.1.141.

Zur digitalen Publikation

Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

Eur Heart J. 2004 Jan;25(1):10-6. doi: 10.1016/s0195-668x(03)00468-8.

Zur digitalen Publikation

Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T; Impaired Glucose Tolerance for Atherosclerosis and Diabetes study.

Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study.

Diabetes Care. 2003 Mar;26(3):868-74. doi: 10.2337/diacare.26.3.868.

Zur digitalen Publikation

Hanefeld M, Fischer S.

[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].

MMW Fortschr Med. 2003 Feb 27;145(9):30-4.

Zur digitalen Publikation

Hanefeld M, Sachse G.

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.

Diabetes Obes Metab. 2002 Nov;4(6):415-23. doi: 10.1046/j.1463-1326.2002.00237.x.

Zur digitalen Publikation

Temelkova-Kurktschiev T, Koehler C, Henkel E, Hanefeld M.

Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.

Cardiovasc Res. 2002 Nov;56(2):277-83. doi: 10.1016/s0008-6363(02)00547-3.

Zur digitalen Publikation

Temelkova-Kurktschiev T.

[Significance of postprandial glucose peaks for development of diabetic macroangiopathy].

Ther Umsch. 2002 Aug;59(8):411-4. doi: 10.1024/0040-5930.59.8.411.

Zur digitalen Publikation

Hanefeld M, Fischer S.

[Differential type 2 diabetes therapy based on pathophysiological aspects].

Ther Umsch. 2002 Aug;59(8):393-401. doi: 10.1024/0040-5930.59.8.393.

Zur digitalen Publikation

Hanefeld M.

Postprandial hyperglycaemia: noxious effects on the vessel wall.

Int J Clin Pract Suppl. 2002 Jul;(129):45-50.

Zur digitalen Publikation

Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M.

Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.

Metabolism. 2002 Jun;51(6):743-9. doi: 10.1053/meta.2002.32804.

Zur digitalen Publikation

Henkel E, Köhler C, Temelkova-Kurktschiev T, Hanefeld M.

[Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study].

Dtsch Med Wochenschr. 2002 May 3;127(18):953-7. doi: 10.1055/s-2002-26731.

Zur digitalen Publikation

Hanefeld M, Temelkova-Kurktschiev T.

Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.

Nutr Metab Cardiovasc Dis. 2002 Apr;12(2):98-107.

Zur digitalen Publikation

Henkel E, Temelkova-Kurktschiev T, Koehler C, Pietzsch J, Leonhardt W, Hanefeld M.

Impaired glucose tolerance is not associated with lipid intolerance.

Diabetes Nutr Metab. 2002 Apr;15(2):84-90.

Zur digitalen Publikation

Hanefeld M, Köhler C.

[The metabolic syndrome and its epidemiologic dimensions in historical perspective].

Z Arztl Fortbild Qualitatssich. 2002 Mar;96(3):183-8.

Zur digitalen Publikation

Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, Fischer S.

Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.

Diabetes Res Clin Pract. 2002 Mar;55(3):221-7. doi: 10.1016/s0168-8227(01)00347-3.

Zur digitalen Publikation

Temelkova-Kurktschiev TS, Hanefeld M.

Oral glucose tolerance test: to be or not to be performed?

Clin Lab. 2002;48(3-4):143-52.

Zur digitalen Publikation

Henkel E, Hanefeld M.

[Hyperlipidemia and fibrates with special reference to diabetes].

Herz. 2001 Dec;26(8):523-30. doi: 10.1007/pl00002057.

Zur digitalen Publikation

Hanefeld M, Belcher G.

Safety profile of pioglitazone.

Int J Clin Pract Suppl. 2001 Sep;(121):27-31.

Zur digitalen Publikation

Hanefeld M.

Pharmacokinetics and clinical efficacy of pioglitazone.

Int J Clin Pract Suppl. 2001 Sep;(121):19-25.

Zur digitalen Publikation

Hanefeld M.

Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor.

Int J Clin Pract. 2001 Jul-Aug;55(6):399-405.

Zur digitalen Publikation

Temelkova-Kurktschiev T, Fischer S, Koehler C, Mennicken G, Henkel E, Hanefeld M.

[Intima-media thickness in healthy probands without risk factors for arteriosclerosis].

Dtsch Med Wochenschr. 2001 Feb 23;126(8):193-7. doi: 10.1055/s-2001-11317.

Zur digitalen Publikation

Domainname:	www.g-wt.de
Ablauf:	30 Tage
Speicherort:	Localstorage
Beschreibung:	Speichert die Privacy Level Einstellungen aus dem Cookie Consent Tool "Privacy Manager".

Domainname:	www.g-wt.de
Ablauf:	30 Tage
Speicherort:	Localstorage
Beschreibung:	Speichert die Speicherdauer der Privacy Level Einstellungen aus dem Cookie Consent Tool "Privacy Manager".

GWT - Unser Erfolg spiegelt sich in den Publikationen unserer Expert:innen wider!

2024

Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease.

2023

Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis.

Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.

Detect Acute Porphyrias in Emergency Departments (DePorED) - a pilot study.

Clinical course of new-onset Crohn's disease in children and adolescents in dependency of age, initial location, initial severity level and therapy over the period 2000-2014 based on the Saxon Pediatric IBD-Registry in Germany.

Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol).

Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis.

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD): rationale, aims and design of a nationwide prospective registry.

Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.

2022

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.

Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.

Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry.

Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.

2021

Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.

Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.

2020

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.

Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.

Risk stratification in pulmonary arterial hypertension using Bayesian analysis.

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.

Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry.

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.

Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.

2019

Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report.

2018

The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.

Sudomotor Testing of Diabetes Polyneuropathy.

Effects of metoprolol on aquatic invertebrates in artificial indoor streams.

Fibre supplementation for the prevention of type 2 diabetes and improvement of glucose metabolism: the randomised controlled Optimal Fibre Trial (OptiFiT).

Urinary Lipidomics: evidence for multiple sources and sexual dimorphism in healthy individuals.

Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

2017

A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

Serum metabolic signatures in patients with overt hepatic encephalopathy.

Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes.

The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism.

Evaluation of direct oral anticoagulants in superficial-vein thrombosis - Authors' reply.

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.

Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

Health effects of metoprolol in epibenthic and endobenthic invertebrates-A basis to validate future in vitro biotests for effect-based biomonitoring.

2016

Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases.

Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Serum and Plasma Levels of Vascular Endothelial Growth Factors in Relation to Quality of Glucose Control, Biomarkers of Inflammation, and Diabetic Nephropathy.

Hypoglycemia and Cardiovascular Risk: Is There a Major Link?

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials.

The metabolic vascular syndrome - guide to an individualized treatment.

Introduction to Hanefeld Symposium: 40+ years of metabolic syndrome.

Determinants of mortality in patients with type 2 diabetes: a review.

Cardiometabolic crosstalk in obesity-associated arterial hypertension.

2015

Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies.

Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions.

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).